Neurocritical Care News

The National Football League and the NFL Players Association have issued a joint statement finalizing review of the league’s concussion protocol, which now prohibits a player from returning to a game if diagnosed with ataxia.

Neurological disorders like epilepsy can have significant, life-altering implications for patients, their families and caregivers.

The FDA has approved Relyvrio, an oral, fixed-dose combination therapy for the treatment of adults with ALS, Amylyx Pharmaceuticals Inc. announced in a press release.

The NIH has awarded a $10.7 million 5-year renewal grant to Cleveland Clinic to expand a national research consortium focused on improving the diagnosis and treatments for dementia with Lewy bodies.

Pharmaceutical companies Biogen and Eisai announced results from a phase 3 trial that demonstrated treatment with lecanemab reduced cognitive decline by 27% after 18 months compared with placebo.

Monkeypox should be considered in high-risk populations who present with neurologic symptoms, warranting the need for serology and PCR testing of blood and spinal fluid, researchers wrote in JAMA Neurology.

Results of a recently released poll revealed that 77% of small business owners said they have prioritized mental health since the onset of the COVID-19 pandemic.

A single, 500 mg dose of rituximab was associated with greater probability of minimal myasthenia gravis manifestations and reduced the need for rescue medications compared with placebo, researchers reported in JAMA Neurology.

Although it was well tolerated, the anti-amyloid antibody crenezumab did not reduce clinical decline in patients with Alzheimer's disease, researchers reported in JAMA Neurology.

The FDA and NIH announced the launch of the Critical Path for Rare Neurodegenerative Diseases, a public-private partnership aimed to advance the understanding of neurodegenerative diseases and the development of treatments.